myelomasociety.org
Categoría: Business
99
/ 100 de confianza
Basado en los hallazgos del análisis en el momento de la evaluación
Sin amenazas detectadas
¿Es este su sitio web?
Muestre a los visitantes que su sitio es seguro
Añada la PCrisk Trust Badge, reanalizada cada 24 horas en busca de malware y amenazas. Un sello de seguridad visible tranquiliza a los visitantes, y esa confianza puede convertirse en más ventas, registros y llamadas.
Reanálisis automáticos
Verificado por más de 90 motores de seguridad
WordPress · Shopify · Wix · cualquier sitio
Obtenga su Trust Badge
Copiar y pegar · configuración rápida
Análisis de seguridad de PCrisk en tus resultados de Google
Añade PCrisk como fuente preferida y daremos prioridad a nuestros informes de análisis y guías de eliminación en Google.
Añadir PCrisk como fuente preferida
Captura de pantalla de myelomasociety.org
Capturada 17 ago 2026
https://myelomasociety.org
16 años
Sin ranking - Este sitio web no aparece en la lista principal de Tranco
No listado (91 comprobados)
✓ Válido (TLS)
Google Cloud (us-east1)
North Charleston, United States
nginx
WordPress
104.196.208.135
Información del dominio y WHOIS
Registrador
Squarespace Domains II LLC
Registrado
16 de diciembre de 2009
Caduca
16 de diciembre de 2026
Servidores de nombres
ns-cloud-a2.googledomains.com
DNSSEC
Firmado
Hosting
Google Cloud (us-east1)
Comprobación de reputación y amenazas
91 motores de seguridad comprobados
0
No marcado
Fuentes directas de bases de datos de amenazas
Google
No listado
Spamhaus DBL
No listado
SURBL
No listado
Spamhaus ZEN
No listado
Barracuda
No listado
SpamCop
No listado
Spamhaus ZRD
No listado
URLhaus
No listado
Phishtank
No listado
QBMA
No listado
Ver resultados detallados del motor en VirusTotal
Resumen del análisis de archivos
Con tecnología de Quttera Engine
61 archivos analizados
Sin amenazas
61
Riesgo bajo
0
Riesgo medio
0
Riesgo alto
0
Sin amenazas
Riesgo bajo
Riesgo medio
Riesgo alto
www.myelomasociety.org.http-redirect
96 B
Sin amenazas
www.myelomasociety.org/?page_id=2928&preview=true
217.2 KB
Sin amenazas
www.myelomasociety.org/about%3Ablank
60 B
Sin amenazas
www.myelomasociety.org/#
312.7 KB
Sin amenazas
www.myelomasociety.org/education/#
145.0 KB
Sin amenazas
www.myelomasociety.org/imsound/#
156.2 KB
Sin amenazas
www.myelomasociety.org/translational-research-award/#
220.5 KB
Sin amenazas
www.myelomasociety.org/donate/#
183.9 KB
Sin amenazas
www.myelomasociety.org/publications/#
145.3 KB
Sin amenazas
www.myelomasociety.org/glo-ims/#
142.2 KB
Sin amenazas
Mostrar 51 más...
www.myelomasociety.org/events/#
156.3 KB
Sin amenazas
www.myelomasociety.org/advocacy/about%3Ablank
60 B
Sin amenazas
www.myelomasociety.org/advocacy/#
142.6 KB
Sin amenazas
www.myelomasociety.org/awards/about%3Ablank
60 B
Sin amenazas
www.myelomasociety.org/awards/#
142.7 KB
Sin amenazas
www.myelomasociety.org/contact/#
141.6 KB
Sin amenazas
www.myelomasociety.org/ims-news-room/#
144.0 KB
Sin amenazas
www.myelomasociety.org/ims-connect/#
145.2 KB
Sin amenazas
www.myelomasociety.org/meeting-materials/#
142.0 KB
Sin amenazas
www.myelomasociety.org/about-us/about%3Ablank
60 B
Sin amenazas
www.myelomasociety.org/about-us/#
144.3 KB
Sin amenazas
www.myelomasociety.org/grants/#
143.8 KB
Sin amenazas
www.myelomasociety.org/renew-membership/#
202.5 KB
Sin amenazas
www.myelomasociety.org/career-development-award/#
185.6 KB
Sin amenazas
www.myelomasociety.org/membership/#
142.7 KB
Sin amenazas
www.google.com/recaptcha/api.js?hl=en&&ver=7.0.4#038;render=explicit
976 B
Sin amenazas
player.vimeo.com/video/1122004834?h=91c3f1bf02
5.0 KB
Sin amenazas
www.myelomasociety.org/feed/mp3/#
34.1 KB
Sin amenazas
www.myelomasociety.org/events/8th-immune-effector-cell-therapies-in-multiple-myeloma-workshop/#
143.3 KB
Sin amenazas
www.myelomasociety.org/events/23rd-ims-annual-meeting/#
147.7 KB
Sin amenazas
www.myelomasociety.org/events/novel-immune-therapies-workshop/#
144.8 KB
Sin amenazas
www.myelomasociety.org/events/ims-community-webinar-series-optimizing-the-use-of-adcs-and-tcrts/#
149.2 KB
Sin amenazas
www.myelomasociety.org/events/fda-ims-joint-workshop-defining-patient-populations-for-clinical-trials-in-multiple-myeloma/#
146.8 KB
Sin amenazas
www.myelomasociety.org/advocacy/tmap/about%3Ablank
60 B
Sin amenazas
www.myelomasociety.org/advocacy/tmap/#
144.4 KB
Sin amenazas
www.myelomasociety.org/awards/waldenstrom-award/about%3Ablank
60 B
Sin amenazas
www.myelomasociety.org/awards/waldenstrom-award/#
146.8 KB
Sin amenazas
www.myelomasociety.org/awards/ken-anderson-young-investigator-award/about%3Ablank
60 B
Sin amenazas
www.myelomasociety.org/awards/ken-anderson-young-investigator-award/#
146.6 KB
Sin amenazas
www.myelomasociety.org/awards/bart-barlogie-young-investigator-award/about%3Ablank
60 B
Sin amenazas
www.myelomasociety.org/awards/bart-barlogie-young-investigator-award/#
146.5 KB
Sin amenazas
www.myelomasociety.org/award/a-scalable-manufacturing-platform-for-externally-controllable-universal-car-t-cell-products/#
147.3 KB
Sin amenazas
www.myelomasociety.org/officers/masahiro-abe-md-phd/#
145.3 KB
Sin amenazas
www.myelomasociety.org/officers/kenneth-anderson-md/#
146.6 KB
Sin amenazas
www.myelomasociety.org/officers/suzanne-lentzsch-md-phd/#
146.8 KB
Sin amenazas
www.myelomasociety.org/officers/katja-weisel-md/#
147.0 KB
Sin amenazas
www.myelomasociety.org/officers/19271/#
146.1 KB
Sin amenazas
www.myelomasociety.org/officers/chandramouli-nagarajan-mbbs-frcpedin-frcpathuk/#
145.6 KB
Sin amenazas
www.myelomasociety.org/officers/philippe-moreau-md/#
145.2 KB
Sin amenazas
www.myelomasociety.org/officers/elena-zamagni-md-phd/#
146.5 KB
Sin amenazas
www.myelomasociety.org/officers/noopur-s-raje-md/#
145.0 KB
Sin amenazas
www.myelomasociety.org/officers/nikhil-c-munshi-md/#
147.3 KB
Sin amenazas
www.myelomasociety.org/officers/jesus-san-miguel-md-phd/#
145.7 KB
Sin amenazas
www.myelomasociety.org/officers/shaji-kumar-md/#
144.6 KB
Sin amenazas
www.myelomasociety.org/officers/maria-victoria-mateos-md-phd/#
145.9 KB
Sin amenazas
www.myelomasociety.org/officers/saad-z-usmani-md-mba-fcap/#
146.6 KB
Sin amenazas
www.myelomasociety.org/officers/robert-a-kyle-md/#
145.8 KB
Sin amenazas
www.myelomasociety.org/about-us/officers/about%3Ablank
60 B
Sin amenazas
www.myelomasociety.org/about-us/officers/#
151.2 KB
Sin amenazas
www.myelomasociety.org/about-us/member-details/about%3Ablank
60 B
Sin amenazas
www.myelomasociety.org/about-us/member-details/#
217.2 KB
Sin amenazas
Enlaces externos y dominios
411
Enlaces externos
Todo limpio
1
Iframes
Limpio
27
Dominios referenciados
Todo limpio
0
Recursos marcados
Nada detectado
http://browsehappy.com/No marcado
http://myelomasociety.org/about-us/No marcado
http://myelomasociety.org/about-us/member-details/No marcado
http://myelomasociety.org/about-us/officers/No marcado
http://myelomasociety.org/about:blankNo marcado
http://myelomasociety.org/advocacy/No marcado
http://myelomasociety.org/advocacy/tmap/No marcado
http://myelomasociety.org/award/a-scalable-manufacturing-platform-for-externally-controllable-universal-car-t-cell-products/No marcado
http://myelomasociety.org/awards/No marcado
http://myelomasociety.org/awards/bart-barlogie-young-investigator-award/No marcado
http://myelomasociety.org/awards/ken-anderson-young-investigator-award/No marcado
http://myelomasociety.org/awards/waldenstrom-award/No marcado
http://myelomasociety.org/career-development-award/No marcado
http://myelomasociety.org/contact/No marcado
http://myelomasociety.org/donate/No marcado
Mostrar 396 más...
http://myelomasociety.org/education/No marcado
http://myelomasociety.org/events/No marcado
http://myelomasociety.org/events/23rd-ims-annual-meeting/No marcado
http://myelomasociety.org/events/8th-immune-effector-cell-therapies-in-multiple-myeloma-workshop/No marcado
http://myelomasociety.org/events/fda-ims-joint-workshop-defining-patient-populations-for-clinical-trials-in-multiple-myeloma/No marcado
http://myelomasociety.org/events/ims-community-webinar-series-optimizing-the-use-of-adcs-and-tcrts/No marcado
http://myelomasociety.org/events/novel-immune-therapies-workshop/No marcado
http://myelomasociety.org/glo-ims/No marcado
http://myelomasociety.org/grants/No marcado
http://myelomasociety.org/ims-connect/No marcado
http://myelomasociety.org/ims-news-room/No marcado
http://myelomasociety.org/imsound/No marcado
http://myelomasociety.org/meeting-materials/No marcado
http://myelomasociety.org/membership/No marcado
http://myelomasociety.org/officers/19271/No marcado
http://myelomasociety.org/officers/chandramouli-nagarajan-mbbs-frcpedin-frcpathuk/No marcado
http://myelomasociety.org/officers/elena-zamagni-md-phd/No marcado
http://myelomasociety.org/officers/jesus-san-miguel-md-phd/No marcado
http://myelomasociety.org/officers/katja-weisel-md/No marcado
http://myelomasociety.org/officers/kenneth-anderson-md/No marcado
http://myelomasociety.org/officers/maria-victoria-mateos-md-phd/No marcado
http://myelomasociety.org/officers/masahiro-abe-md-phd/No marcado
http://myelomasociety.org/officers/nikhil-c-munshi-md/No marcado
http://myelomasociety.org/officers/noopur-s-raje-md/No marcado
http://myelomasociety.org/officers/philippe-moreau-md/No marcado
http://myelomasociety.org/officers/robert-a-kyle-md/No marcado
http://myelomasociety.org/officers/saad-z-usmani-md-mba-fcap/No marcado
http://myelomasociety.org/officers/shaji-kumar-md/No marcado
http://myelomasociety.org/officers/suzanne-lentzsch-md-phd/No marcado
http://myelomasociety.org/publications/No marcado
http://myelomasociety.org/renew-membership/No marcado
http://myelomasociety.org/rwlkndntodz70pncjlz+vs5lfhfs7lixda/nQ6BMfy4NA2JV8GvaNOriauzE38L2WqrHhMJJUcx+XNd2b1cxprmEXCC5WRqcvN4kZNMzea4LDY%3DNo marcado
http://myelomasociety.org/translational-research-award/No marcado
http://myelomasociety.org/zotknmvcufmka+gcznuu6s0sonmy8vvthz6jnd4wwup4krocefqzpoqm7cr93knvfnyeidjhbj8t7xaehzwvmjntmqex4cl9vwjx0/baf2tMms%3DNo marcado
http://tmap.myelomasociety.org/No marcado
https://bsky.app/profile/myeloma-society.bsky.socialNo marcado
https://cdn.jsdelivr.net/npm/tsparticles@1.18.3/dist/tsparticles.min.jsNo marcado
https://challenges.cloudflare.com/turnstile/v0/api.js?onload%3DturnstileLoadNo marcado
https://events.jspargo.com/ims26/CUSTOM/DGHOProgram2026.pdfNo marcado
https://events.jspargo.com/ims26/CUSTOM/IMS2026Program.pdf?__hstc%3D113688920.2b677668b1c0d347e01494227127fa6c.1775135324106.1779466033070.1779705887942.56&%3B__hssc%3D113688920.1.1779705887942&%3B__hsfp%3Dbf1414f9ef3b88063871ea845a26dec4No marcado
https://events.jspargo.com/ims26/CUSTOM/IMSCommunityWebinarCentralAug.pdfNo marcado
https://events.jspargo.com/ims26/CUSTOM/IMSCommunityWebinarCentralJul.pdfNo marcado
https://events.jspargo.com/ims26/CUSTOM/IMSCommunityWebinarEastAug.pdfNo marcado
https://events.jspargo.com/ims26/CUSTOM/IMSCommunityWebinarEastJun.pdfNo marcado
https://events.jspargo.com/ims26/CUSTOM/IMSCommunityWebinarWestAug.pdfNo marcado
https://events.jspargo.com/ims26/CUSTOM/IMSCommunityWebinarWestJul.pdfNo marcado
https://fonts.googleapis.com/css2?family%3DOpen+Sans:ital@0%3B1&%3Bfamily%3DPlayfair+Display:ital,wght@0,400%3B0,700%3B1,400%3B1,700&%3Bdisplay%3DswapNo marcado
https://fonts.gstatic.comNo marcado
https://ims26.myexpoonline.com/homeNo marcado
https://myeloma.wpengine.com/about-us/officers/No marcado
https://myeloma.wpengine.com/wp-content/uploads/2021/02/COI-Policy-IMS.pdfNo marcado
https://myeloma.wpengine.com/wp-content/uploads/2021/03/IMSAltLogo.pngNo marcado
https://myelomasociety.flexigrant.com/startapplication.aspx?id%3D16381No marcado
https://myelomasociety.org/grants/ims-career-development-award/No marcado
https://myelomasociety.org/past-events/No marcado
https://myelomasociety.org/privacy-policy/No marcado
https://myelomasociety.org/publications/No marcado
https://myelomasociety.org/wp-content/uploads/2021/03/PM-COVID-vaccination-in-MM-guidelines-The-Final.pdfNo marcado
https://player.vimeo.com/video/1122004834?h%3D91c3f1bf02No marcado
https://www.eventcreate.com/e/communitywebinarseries2026No marcado
https://www.eventcreate.com/e/fda-ims-joint-workshop2024No marcado
https://www.eventcreate.com/e/imsdgho2026No marcado
https://www.google.com/recaptcha/api.js?hl%3Den&%3B&%3Bver%3D7.0.4#038%3Brender%3DexplicitNo marcado
https://www.googletagmanager.com/gtag/js?id%3DAW-11265840522No marcado
https://www.googletagmanager.com/gtag/js?id%3DGT-MK9LQQBNo marcado
https://www.gstatic.com/recaptcha/releases/XOqlk8PL_yVx6IdpLbpXdiLy/recaptcha__en.jsNo marcado
https://www.linkedin.com/company/19160726/admin/dashboard/No marcado
https://www.myelomasociety.orgNo marcado
https://www.myelomasociety.org/No marcado
https://www.myelomasociety.org/?p%3D18549No marcado
https://www.myelomasociety.org/?p%3D18605No marcado
https://www.myelomasociety.org/?p%3D18607No marcado
https://www.myelomasociety.org/?p%3D18610No marcado
https://www.myelomasociety.org/?page_id%3D2928&%3Bpreview%3DtrueNo marcado
https://www.myelomasociety.org/?post_type%3Dpodcast&%3Bp%3D18550&%3Bpreview%3DtrueNo marcado
https://www.myelomasociety.org/about-us/No marcado
https://www.myelomasociety.org/about-us/member-details/No marcado
https://www.myelomasociety.org/about-us/member-details/membership-information/No marcado
https://www.myelomasociety.org/about-us/officers/No marcado
https://www.myelomasociety.org/advocacy/No marcado
https://www.myelomasociety.org/advocacy/tmap/No marcado
https://www.myelomasociety.org/award/a-scalable-manufacturing-platform-for-externally-controllable-universal-car-t-cell-products/No marcado
https://www.myelomasociety.org/award/amyloid-targeting-car-macrophage-therapy-against-al-amyloidosis/No marcado
https://www.myelomasociety.org/award/ancestrality-of-genomic-alterations-in-multiple-myeloma-impact-on-the-clonal-evolution-and-on-the-minimal-residual-disease-dynamics/No marcado
https://www.myelomasociety.org/award/apobec3b-as-a-biomarker-and-therapeutic-vulnerability-in-tp53-aberrant-multiple-myeloma/No marcado
https://www.myelomasociety.org/award/application-of-mass-spectrometry-for-the-diagnosis-and-monitoring-of-real-life-patients-with-monoclonal-gammopathies/No marcado
https://www.myelomasociety.org/award/armored-cars-to-overcome-sialylation-mediated-resistance-in-multiple-myeloma/No marcado
https://www.myelomasociety.org/award/batmman-bone-marrow-adipocytes-in-the-multiple-myeloma-niche/No marcado
https://www.myelomasociety.org/award/bcl2l1-armored-car-t-cells-overcome-exhaustion-and-enhance-persistence-in-multiple-myeloma/No marcado
https://www.myelomasociety.org/award/bcma-inkt-car-for-the-treatment-of-multiple-myeloma/No marcado
https://www.myelomasociety.org/award/biomarkers-for-monoclonal-gammopathy-of-undetermined-significance-mgus-and-multiple-myeloma/No marcado
https://www.myelomasociety.org/award/bone-marrow-inflammation-as-driver-of-multiple-myeloma-persistence-and-relapse/No marcado
https://www.myelomasociety.org/award/characterizing-the-emergence-of-t-cell-dysfunction-as-a-cause-of-therapy-failure-and-disease-progression-in-multiple-myeloma/No marcado
https://www.myelomasociety.org/award/chimeric-antigen-receptor-t-cells-secreting-il-12-and-anti-il-6-to-enhance-responses-in-multiple-myeloma/No marcado
https://www.myelomasociety.org/award/comprehensive-exploration-of-molecular-pathways-and-biomarkers-in-myeloma-induced-bone-disease-a-multi-omics-approach-for-personalized-therapeutic-management/No marcado
https://www.myelomasociety.org/award/comprehensive-genomic-and-immune-characterization-of-response-and-resistance-to-daratumumab-based-quadruplet-induction-therapy/No marcado
https://www.myelomasociety.org/award/convad-cart-next-generation-bcma-cart-cells-with-modular-targeting-capacities/No marcado
https://www.myelomasociety.org/award/correlation-between-unfolded-protein-response-upr-markers-and-thrombosis-in-multiple-myeloma/No marcado
https://www.myelomasociety.org/award/deciphering-the-human-plasma-cell-niche-and-its-transformation-in-multiple-myeloma-by-highly-multiplexed-tissue-imaging/No marcado
https://www.myelomasociety.org/award/defining-the-risk-of-clonal-hematopoiesis-and-therapy-related-myeloid-neoplasms-in-multiple-myeloma-patients-receiving-asct-and-lenalidomide-maintenance/No marcado
https://www.myelomasociety.org/award/democratizing-multiple-myeloma-car-t-cell-therapy-by-in-situ-programming-of-virus-specific-t-cells/No marcado
https://www.myelomasociety.org/award/destiny-detecting-spatial-heterogeneity-in-multiple-myeloma-patients-through-a-liquid-biopsy-approach/No marcado
https://www.myelomasociety.org/award/development-of-an-optimized-dual-targeted-tandem-vh-only-fully-human-car-to-generate-long-term-durable-remission-with-adoptive-cellular-therapy-for-multiple-myeloma/No marcado
https://www.myelomasociety.org/award/development-of-novel-extracellular-vesicle-ev-exosome-based-treatment-for-multiple-myeloma-therapeutic-potential-of-mir125b-containing-osteoblast-derived-evs/No marcado
https://www.myelomasociety.org/award/development-of-novel-targeted-therapies-for-multiple-myeloma/No marcado
https://www.myelomasociety.org/award/discover-nutrients-understanding-the-relationship-between-nutrition-and-microbiome-in-mm/No marcado
https://www.myelomasociety.org/award/discovering-and-targeting-unprecedented-mitochondrial-vulnerabilities-against-multiple-myeloma/No marcado
https://www.myelomasociety.org/award/dissect-the-mechanisms-by-which-cst6n137d-enhances-the-efficacy-of-car-t-cell-therapy-in-myeloma/No marcado
https://www.myelomasociety.org/award/dissecting-and-appraising-novel-mitochondrial-vulnerabilities-against-multiple-myeloma/No marcado
https://www.myelomasociety.org/award/dissecting-the-functional-role-of-apobec3b-in-multiple-myeloma/No marcado
https://www.myelomasociety.org/award/dissecting-the-mechanisms-of-multiple-myeloma-mm-resistance-to-natural-killer-nk-cells-and-the-role-of-nk-cells-macrophage-interaction-in-mm-immune-evasion/No marcado
https://www.myelomasociety.org/award/early-detection-and-intervention-in-smoldering-multiple-myeloma-population-based-screening-and-treatment-edit-smm/No marcado
https://www.myelomasociety.org/award/evaluating-nkp30-directed-bispecific-nk-cell-engagers-for-multiple-myeloma-therapy/No marcado
https://www.myelomasociety.org/award/evaluation-of-single-nucleotide-polymorphisms-of-brca1-cdkn1a-tp53bp-and-xrcc1-in-multiple-myeloma-patients-undergoing-hematopoietic-stem-cells-transplant-and-their-association-with-clinical-outcom/No marcado
https://www.myelomasociety.org/award/evaluation-of-single-nucleotide-variants-in-dna-repair-and-cell-cycle-control-genes-in-multiple-myeloma-patients-undergoing-hematopoietic-stem-cell-transplant-and-their-association-with-clinical-outco/No marcado
https://www.myelomasociety.org/award/exploiting-translation-control-vulnerabilities-imposed-by-antibody-secretion-in-multiple-myeloma/No marcado
https://www.myelomasociety.org/award/exploring-apobecs-as-therapeutic-vulnerabilities-in-multiple-myeloma/No marcado
https://www.myelomasociety.org/award/flow-cytometry-as-a-tool-for-the-study-of-the-tumor-microenvironment-in-multiple-myeloma/No marcado
https://www.myelomasociety.org/award/functional-screens-on-single-cell-transcriptomes-of-genotypically-defined-minimal-residual-disease-cells-to-unravel-specific-vulnerabilities-of-treatment-resistant-multiple-myeloma-future/No marcado
https://www.myelomasociety.org/award/gck-a-new-therapeutic-target-for-undruggable-ras-in-myeloma-treatment/No marcado
https://www.myelomasociety.org/award/gck-inhibition-as-a-new-therapeutical-approach-in-rasmut-myeloma-and-possible-strategy-to-overcome-therapy-resistance/No marcado
https://www.myelomasociety.org/award/glutamine-metabolism-as-new-marker-and-diagnostic-tool-for-bone-diseases-in-mm-patients/No marcado
https://www.myelomasociety.org/award/how-to-engage-t-cell-in-myeloma/No marcado
https://www.myelomasociety.org/award/identify-high-risk-disease-in-multiple-myeloma-through-single-cell-detection-of-highly-proliferative-pr-cells/No marcado
https://www.myelomasociety.org/award/identifying-mechanisms-of-response-and-resistance-to-bcma-car-t-therapy-in-multiple-myeloma-and-extramedullary-disease/No marcado
https://www.myelomasociety.org/award/immagine/No marcado
https://www.myelomasociety.org/award/immune-cell-contribution-to-drug-resistance-in-multiple-myeloma/No marcado
https://www.myelomasociety.org/award/immunogenomics-guided-adaptive-cellular-therapies-in-multiple-myeloma/No marcado
https://www.myelomasociety.org/award/immunotherapy-for-multiple-myeloma-a-new-generation-of-chimeric-antigen-receptors-and-immune-checkpoint-blockade/No marcado
https://www.myelomasociety.org/award/improving-immune-surveillance-in-high-risk-multiple-myeloma-patients/No marcado
https://www.myelomasociety.org/award/improving-prognosis-of-progression-risk-in-multiple-myeloma-precursors-through-single-cell-sequencing-based-genomic-and-immune-microenvironment-profiling-2/No marcado
https://www.myelomasociety.org/award/investigating-creb1-signaling-as-a-novel-therapeutic-target-in-multiple-myeloma/No marcado
https://www.myelomasociety.org/award/investigating-heme-induced-effector-car-t-cells-for-multiple-myeloma-therapy/No marcado
https://www.myelomasociety.org/award/investigating-the-impact-of-vaccinations-on-the-development-and-course-of-monoclonal-gammopathies-a-comprehensive-analysis/No marcado
https://www.myelomasociety.org/award/investigating-the-molecular-mechanisms-of-microenvironment-dependent-immune-escape-to-natural-killer-cells-in-myeloma-to-uncover-biomarkers-for-rational-combination-treatment-strategie/No marcado
https://www.myelomasociety.org/award/investigation-of-the-molecular-mechanism-of-gck-inhibition-as-therapeutic-approach-in-multiple-myeloma/No marcado
https://www.myelomasociety.org/award/liquid-biopsy-in-myeloma-to-inform-outcome-and-treatment-decisions/No marcado
https://www.myelomasociety.org/award/modeling-unraveling-and-beating-acquired-resistance-to-bcma-and-gprc5d-targeted-agents-in-multiple-myeloma-2/No marcado
https://www.myelomasociety.org/award/modeling-unraveling-and-beating-acquired-resistance-to-bcma-and-gprc5d-targeted-agents-in-multiple-myeloma/No marcado
https://www.myelomasociety.org/award/molecular-characterization-and-therapeutic-targeting-of-protein-kinase-d2-in-t414-multiple-myeloma/No marcado
https://www.myelomasociety.org/award/multimodal-investigation-of-myeloma-recognizing-t-cells-their-transcriptional-features-and-clinical-relevance/No marcado
https://www.myelomasociety.org/award/nanobody-based-il-18-armored-bcma-baff-r-dual-car-t-cells-to-overcome-treatment-failure-in-multiple-myeloma/No marcado
https://www.myelomasociety.org/award/novel-immunotherapy-investigation-and-characterization-of-immune-escape-mechanisms-to-natural-killer-cells-in-multiple-myeloma/No marcado
https://www.myelomasociety.org/award/optimizing-melphalan-dose-among-older-adults-with-multiple-myeloma-receiving-autologous-stem-cell-transplantation/No marcado
https://www.myelomasociety.org/award/patterns-of-relapse-from-complete-response-during-different-maintenance-strategies/No marcado
https://www.myelomasociety.org/award/pnc-27-a-novel-effective-strategy-for-targeting-the-achilles-heel-of-multiple-myeloma/No marcado
https://www.myelomasociety.org/award/role-of-flow-cytometry-and-especially-its-use-in-the-definition-of-the-measurable-residual-disease-mrd-in-multiple-myeloma/No marcado
https://www.myelomasociety.org/award/shield-mm-a-modular-multiplex-shrna-platform-to-enhance-functional-persistence-of-academic-anti-bcma-car-t-cells-ari0002h-in-multiple-myeloma/No marcado
https://www.myelomasociety.org/award/single-cell-dissection-of-autologous-apheresis-products-to-predict-successful-manufacturing-safe-application-and-response-to-chimeric-antigen-receptor-t-cells-in-newly-diagnosed-and-relapsed-myeloma/No marcado
https://www.myelomasociety.org/award/spatial-and-deep-learning-approaches-to-predict-early-progression-in-smoldering-multiple-myeloma/No marcado
https://www.myelomasociety.org/award/spatial-and-temporal-tumor-genomic-heterogeneity-in-extramedullary-multiple-myeloma-and-solitary-plasmacytoma-with-minimal-marrow-involvement/No marcado
https://www.myelomasociety.org/award/systematic-functional-genomics-characterization-of-17p13del-multiple-myeloma/No marcado
https://www.myelomasociety.org/award/targeting-collagen-lair1-for-improving-multiple-myeloma-therapeutic-efficacy/No marcado
https://www.myelomasociety.org/award/targeting-inter-organelle-communication-to-arrest-multiple-myeloma/No marcado
https://www.myelomasociety.org/award/targeting-loss-of-the-tumor-suppressor-tent5c-in-multiple-myeloma/No marcado
https://www.myelomasociety.org/award/targeting-metabolic-switch-of-high-risk-multiple-myeloma-cells-towards-the-design-of-an-exploratory-approach-for-an-unmet-clinical-need/No marcado
https://www.myelomasociety.org/award/targeting-tcf3-addiction-in-multiple-myeloma/No marcado
https://www.myelomasociety.org/award/targeting-tf-cd142-as-a-new-target-for-car-nk-cell-immunotherapy-in-multiple-myeloma/No marcado
https://www.myelomasociety.org/award/targeting-the-bone-marrow-niche-in-multiple-myeloma/No marcado
https://www.myelomasociety.org/award/the-development-of-amyloid-subtype-specific-car-phagocytes-for-al-amyloidosis-therapy/No marcado
https://www.myelomasociety.org/award/the-permissive-immune-microenvironment-is-a-critical-regulator-of-disease-progression-from-smm-to-overt-mm-and-defining-these-alterations-is-critical-for-the-development-of-translational-prognostic-a/No marcado
https://www.myelomasociety.org/award/transforming-multiple-myeloma-care-in-sub-saharan-africa-developing-a-population-specific-next-generation-sequencing-panel-based-on-long-read-whole-genome-sequencing-to-enhance-treatment-outcomes-in/No marcado
https://www.myelomasociety.org/award/uncovering-ferroptosis-mediated-immune-escape-in-del17p-multiple-myeloma/No marcado
https://www.myelomasociety.org/award/unlocking-precision-medicine-in-refractory-multiple-myeloma/No marcado
https://www.myelomasociety.org/award/usbcar-t-using-crispr-2-0-to-generate-universal-slamf7-bcma-car-t-cells-for-treating-multiple-myeloma/No marcado
https://www.myelomasociety.org/awards/No marcado
https://www.myelomasociety.org/awards/bart-barlogie-young-investigator-award/No marcado
https://www.myelomasociety.org/awards/ken-anderson-young-investigator-award/No marcado
https://www.myelomasociety.org/awards/waldenstrom-award/No marcado
https://www.myelomasociety.org/belantamab-mafodotin-bortezomib-and-dexamethasone-vs-daratumumab-bortezomib-and-dexamethasone-in-relapsed-refractory-multiple-myeloma-overall-survival-analysis-and-updated-efficacy-outcomes-of-th/No marcado
https://www.myelomasociety.org/belantamab-mafodotin-bortezomib-and-dexamethasone-vs-daratumumab-bortezomib-and-dexamethasone-in-relapsed-refractory-multiple-myeloma-overall-survival-analysis-and-updated-efficacy-outcomes-of-th/#No marcado
https://www.myelomasociety.org/career-development-award/No marcado
https://www.myelomasociety.org/contact/No marcado
https://www.myelomasociety.org/development-of-an-academic-car-t-in-mm-the-spanish-experience/No marcado
https://www.myelomasociety.org/development-of-an-academic-car-t-in-mm-the-spanish-experience/#No marcado
https://www.myelomasociety.org/do-we-need-pet-ct-to-assess-response-in-mm/No marcado
https://www.myelomasociety.org/do-we-need-pet-ct-to-assess-response-in-mm/#No marcado
https://www.myelomasociety.org/donate/No marcado
https://www.myelomasociety.org/drug-access-in-brazil-equity-actions-between-public-and-private-health-systems/No marcado
https://www.myelomasociety.org/drug-access-in-brazil-equity-actions-between-public-and-private-health-systems/#No marcado
https://www.myelomasociety.org/education/No marcado
https://www.myelomasociety.org/efficacy-and-safety-of-isa-krd-induction-before-response-adapted-consolidation-in-transplant-eligible-newly-diagnosed-multiple-myeloma-an-interim-analysis-of-the-ifm2020-02-midas-study/#No marcado
https://www.myelomasociety.org/events/No marcado
https://www.myelomasociety.org/events/23rd-ims-annual-meeting/No marcado
https://www.myelomasociety.org/events/8th-immune-effector-cell-therapies-in-multiple-myeloma-workshop/No marcado
https://www.myelomasociety.org/events/fda-ims-joint-workshop-defining-patient-populations-for-clinical-trials-in-multiple-myeloma/No marcado
https://www.myelomasociety.org/events/ims-community-webinar-series-optimizing-the-use-of-adcs-and-tcrts/No marcado
https://www.myelomasociety.org/events/novel-immune-therapies-workshop/No marcado
https://www.myelomasociety.org/feed/mp3/No marcado
https://www.myelomasociety.org/findings-from-the-australian-and-new-zealand-myeloma-and-related-diseases-registry/No marcado
https://www.myelomasociety.org/findings-from-the-australian-and-new-zealand-myeloma-and-related-diseases-registry/#No marcado
https://www.myelomasociety.org/first-results-of-a-phase-1-first-in-human-dose-escalation-study-of-isb-2001-a-bcmaxcd38xcd3-targeting-trispecific-antibody-in-patients-with-relapsed-refractory-multiple-myeloma-rrmm/No marcado
https://www.myelomasociety.org/first-results-of-a-phase-1-first-in-human-dose-escalation-study-of-isb-2001-a-bcmaxcd38xcd3-targeting-trispecific-antibody-in-patients-with-relapsed-refractory-multiple-myeloma-rrmm/#No marcado
https://www.myelomasociety.org/frontline-therapy-for-transplant-ineligible-patients-the-european-perspective/No marcado
https://www.myelomasociety.org/frontline-therapy-for-transplant-ineligible-patients-the-european-perspective/#No marcado
https://www.myelomasociety.org/glo-ims/No marcado
https://www.myelomasociety.org/grants/No marcado
https://www.myelomasociety.org/grants/ims-awards-for-exemplary-abstracts/No marcado
https://www.myelomasociety.org/grants/ims-career-development-award/No marcado
https://www.myelomasociety.org/grants/international-myeloma-society-ims-and-paula-and-rodger-riney-foundation-translational-research-grant/No marcado
https://www.myelomasociety.org/importance-of-patient-reported-symptoms-and-health-related-quality-of-life-for-drug-approval-in-mm/#No marcado
https://www.myelomasociety.org/ims-connect/No marcado
https://www.myelomasociety.org/ims-connect/ims-connect-July-3-2026/No marcado
https://www.myelomasociety.org/ims-connect/ims-connect-May-1-2026/No marcado
https://www.myelomasociety.org/ims-connect/ims-connect-May-15-2026/No marcado
https://www.myelomasociety.org/ims-connect/ims-connect-May-8-2026/No marcado
https://www.myelomasociety.org/ims-connect/ims-connect-april-10/No marcado
https://www.myelomasociety.org/ims-connect/ims-connect-april-17-2026/No marcado
https://www.myelomasociety.org/ims-connect/ims-connect-april-24-2026/No marcado
https://www.myelomasociety.org/ims-connect/ims-connect-april-3-2026/No marcado
https://www.myelomasociety.org/ims-connect/ims-connect-december-12-2025/No marcado
https://www.myelomasociety.org/ims-connect/ims-connect-december-19-2025/No marcado
https://www.myelomasociety.org/ims-connect/ims-connect-december-5-2025/No marcado
https://www.myelomasociety.org/ims-connect/ims-connect-february-13/No marcado
https://www.myelomasociety.org/ims-connect/ims-connect-february-20-2026No marcado
https://www.myelomasociety.org/ims-connect/ims-connect-february-27-2026No marcado
https://www.myelomasociety.org/ims-connect/ims-connect-february-6-2026/No marcado
https://www.myelomasociety.org/ims-connect/ims-connect-january-16-2026/No marcado
https://www.myelomasociety.org/ims-connect/ims-connect-january-2-2026/No marcado
https://www.myelomasociety.org/ims-connect/ims-connect-january-23-2026/No marcado
https://www.myelomasociety.org/ims-connect/ims-connect-january-30-2026/No marcado
https://www.myelomasociety.org/ims-connect/ims-connect-january-9-2026/No marcado
https://www.myelomasociety.org/ims-connect/ims-connect-june-12-2026/No marcado
https://www.myelomasociety.org/ims-connect/ims-connect-june-19-2026/No marcado
https://www.myelomasociety.org/ims-connect/ims-connect-june-26-2026/No marcado
https://www.myelomasociety.org/ims-connect/ims-connect-june-5-2026/No marcado
https://www.myelomasociety.org/ims-connect/ims-connect-march-13-2026/No marcado
https://www.myelomasociety.org/ims-connect/ims-connect-march-27-2026/No marcado
https://www.myelomasociety.org/ims-connect/ims-connect-march-6-2026/No marcado
https://www.myelomasociety.org/ims-connect/ims-connect-may-22-2026/No marcado
https://www.myelomasociety.org/ims-connect/ims-connect-may-29-2026/No marcado
https://www.myelomasociety.org/ims-connect/ims-connect-november-14-2025/No marcado
https://www.myelomasociety.org/ims-connect/ims-connect-november-21-2025/No marcado
https://www.myelomasociety.org/ims-connect/ims-connect-november-28-2025/No marcado
https://www.myelomasociety.org/ims-connect/march-20-2026/No marcado
https://www.myelomasociety.org/ims-news-room/No marcado
https://www.myelomasociety.org/ims-news-room/a-statement-from-ims-president-philippe-moreau-after-the-ims-myeloma-cure-summit-definitions-metrics-and-milestones/No marcado
https://www.myelomasociety.org/ims-news-room/international-myeloma-society-asco-and-eha-signal-a-pivotal-moment-in-multiple-myeloma-research/No marcado
https://www.myelomasociety.org/ims-news-room/international-myeloma-society-convenes-global-cure-summit-to-chart-the-scientific-path-to-a-myeloma-cure/No marcado
https://www.myelomasociety.org/ims-news-room/international-myeloma-society-launches-national-webinar-series-to-support-community-use-of-emerging-immunotherapies-in-multiple-myeloma/No marcado
https://www.myelomasociety.org/ims-news-room/international-myeloma-society-opens-abstract-submissions-for-23rd-annual-meeting/No marcado
https://www.myelomasociety.org/ims-news-room/international-myeloma-to-convene-global-experts-in-warsaw-for-4th-annual-workshop-on-genomics/No marcado
https://www.myelomasociety.org/imsound/No marcado
https://www.myelomasociety.org/isatuximab-lenalidomide-bortezomib-and-dexamethasone-induction-therapy-for-transplant-eligible-patients-with-newly-diagnosed-multiple-myeloma-final-progression-free-survival-analysis-of-part-1-of-a/No marcado
https://www.myelomasociety.org/isatuximab-lenalidomide-bortezomib-and-dexamethasone-induction-therapy-for-transplant-eligible-patients-with-newly-diagnosed-multiple-myeloma-final-progression-free-survival-analysis-of-part-1-of-a/#No marcado
https://www.myelomasociety.org/login/?action%3Dforgot_passwordNo marcado
https://www.myelomasociety.org/meeting-materials/No marcado
https://www.myelomasociety.org/membershipNo marcado
https://www.myelomasociety.org/membership/No marcado
https://www.myelomasociety.org/membership/directory/No marcado
https://www.myelomasociety.org/membership/ims-journal/No marcado
https://www.myelomasociety.org/officers/19271/No marcado
https://www.myelomasociety.org/officers/chandramouli-nagarajan-mbbs-frcpedin-frcpathuk/No marcado
https://www.myelomasociety.org/officers/elena-zamagni-md-phd/No marcado
https://www.myelomasociety.org/officers/jesus-san-miguel-md-phd/No marcado
https://www.myelomasociety.org/officers/katja-weisel-md/No marcado
https://www.myelomasociety.org/officers/kenneth-anderson-md/No marcado
https://www.myelomasociety.org/officers/maria-victoria-mateos-md-phd/No marcado
https://www.myelomasociety.org/officers/masahiro-abe-md-phd/No marcado
https://www.myelomasociety.org/officers/nikhil-c-munshi-md/No marcado
https://www.myelomasociety.org/officers/noopur-s-raje-md/No marcado
https://www.myelomasociety.org/officers/philippe-moreau-md/No marcado
https://www.myelomasociety.org/officers/robert-a-kyle-md/No marcado
https://www.myelomasociety.org/officers/saad-z-usmani-md-mba-fcap/No marcado
https://www.myelomasociety.org/officers/shaji-kumar-md/No marcado
https://www.myelomasociety.org/officers/suzanne-lentzsch-md-phd/No marcado
https://www.myelomasociety.org/ongoing-clinical-trials-from-the-nordic-group/No marcado
https://www.myelomasociety.org/ongoing-clinical-trials-from-the-nordic-group/#No marcado
https://www.myelomasociety.org/optimal-therapy-for-young-patients-with-high-risk-disease-the-european-point-of-view/No marcado
https://www.myelomasociety.org/optimal-therapy-for-young-patients-with-high-risk-disease-the-european-point-of-view/#No marcado
https://www.myelomasociety.org/phase-2-registrational-study-of-anitocabtagene-autoleucel-for-the-treatment-of-patients-with-relapsed-and-or-refractory-multiple-myeloma-preliminary-results-from-the-immagine-1-trial/No marcado
https://www.myelomasociety.org/phase-2-registrational-study-of-anitocabtagene-autoleucel-for-the-treatment-of-patients-with-relapsed-and-or-refractory-multiple-myeloma-preliminary-results-from-the-immagine-1-trial/#No marcado
https://www.myelomasociety.org/phase-2-study-of-teclistamab-based-induction-regimens-in-patients-with-transplant-eligible-te-newly-diagnosed-multiple-myeloma-ndmm-results-from-the-gmmg-hd10-dsmm-xx-majestec-5-trial/No marcado
https://www.myelomasociety.org/phase-2-study-of-teclistamab-based-induction-regimens-in-patients-with-transplant-eligible-te-newly-diagnosed-multiple-myeloma-ndmm-results-from-the-gmmg-hd10-dsmm-xx-majestec-5-trial/#No marcado
https://www.myelomasociety.org/phase-3-study-of-teclistamab-tec-in-combination-with-lenalidomide-len-and-tec-alone-versus-len-alone-in-newly-diagnosed-multiple-myeloma-ndmm-as-maintenance-therapy-following-autologous-stem-cel/No marcado
https://www.myelomasociety.org/phase-3-study-of-teclistamab-tec-in-combination-with-lenalidomide-len-and-tec-alone-versus-len-alone-in-newly-diagnosed-multiple-myeloma-ndmm-as-maintenance-therapy-following-autologous-stem-cel/#No marcado
https://www.myelomasociety.org/prevention-of-infections-during-treatment-with-bispecific-antibodies-and-car-t-cells-in-multiple-myeloma/#No marcado
https://www.myelomasociety.org/publications/No marcado
https://www.myelomasociety.org/renew-membership/No marcado
https://www.myelomasociety.org/resistance-to-bispecific-antibodies/No marcado
https://www.myelomasociety.org/resistance-to-bispecific-antibodies/#No marcado
https://www.myelomasociety.org/role-of-tandem-autologous-stem-cell-transplantation-for-the-treatment-of-multiple-myeloma/No marcado
https://www.myelomasociety.org/role-of-tandem-autologous-stem-cell-transplantation-for-the-treatment-of-multiple-myeloma/#No marcado
https://www.myelomasociety.org/safety-and-efficacy-of-standard-of-care-ciltacabtagene-autoleucel-cilta-cel-for-relapsed-refractory-multiple-myeloma-rrmm-real-world-experience-with-updated-follow-up/#No marcado
https://www.myelomasociety.org/single-cell-analyses-of-bone-marrow-immune-microenvironment-in-rrmm-subjects-treated-with-mek1-2-inhibitors-reveal-irf1-mediated-ifn-pdl1-signaling-axes/No marcado
https://www.myelomasociety.org/single-cell-analyses-of-bone-marrow-immune-microenvironment-in-rrmm-subjects-treated-with-mek1-2-inhibitors-reveal-irf1-mediated-ifn-pdl1-signaling-axes/#No marcado
https://www.myelomasociety.org/single-cell-rna-sequencing-of-6-million-tumor-and-immune-cells-in-patients-with-plasma-cell-premalignancy-unveils-co-regulation-of-disease-progression-by-tumor-biology-and-immune-dysregulation/#No marcado
https://www.myelomasociety.org/the-ifm2017-03-phase-3-trial-a-dexamethasone-sparing-regimen-with-daratumumab-and-lenalidomide-for-frail-patients-with-newly-diagnosed-multiple-myeloma/No marcado
https://www.myelomasociety.org/the-ifm2017-03-phase-3-trial-a-dexamethasone-sparing-regimen-with-daratumumab-and-lenalidomide-for-frail-patients-with-newly-diagnosed-multiple-myeloma/#No marcado
https://www.myelomasociety.org/translational-research-award/No marcado
https://www.myelomasociety.org/wp-content/plugins/ajax-search-lite/css/style-simple-red.css?ver%3D4.14.5No marcado
https://www.myelomasociety.org/wp-content/plugins/ajax-search-lite/css/style.basic.css?ver%3D4.14.5No marcado
https://www.myelomasociety.org/wp-content/plugins/ajax-search-lite/js/min/plugin/merged/asl.min.js?ver%3D4787No marcado
https://www.myelomasociety.org/wp-content/plugins/custom-twitter-feeds/css/ctf-styles.min.css?ver%3D2.6.1No marcado
https://www.myelomasociety.org/wp-content/plugins/google-site-kit/dist/assets/js/googlesitekit-consent-mode-86cb52dcb9f2b27ed244.jsNo marcado
https://www.myelomasociety.org/wp-content/plugins/gravityforms/assets/css/dist/basic.min.css?ver%3D2.10.5No marcado
https://www.myelomasociety.org/wp-content/plugins/gravityforms/assets/css/dist/theme-components.min.css?ver%3D2.10.5No marcado
https://www.myelomasociety.org/wp-content/plugins/gravityforms/assets/css/dist/theme.min.css?ver%3D2.10.5No marcado
https://www.myelomasociety.org/wp-content/plugins/gravityforms/assets/js/dist/scripts-theme.min.js?ver%3D301fdc9aa6144168f3b854c4c2c8f6d3No marcado
https://www.myelomasociety.org/wp-content/plugins/gravityforms/assets/js/dist/utils.min.js?ver%3D3f278756f0a3032bed328ff6a9f6c01dNo marcado
https://www.myelomasociety.org/wp-content/plugins/gravityforms/assets/js/dist/vendor-theme.min.js?ver%3D7c651d0ba638ce98b9c65141edddd567No marcado
https://www.myelomasociety.org/wp-content/plugins/gravityforms/js/conditional_logic.min.js?ver%3D2.10.5No marcado
https://www.myelomasociety.org/wp-content/plugins/gravityforms/js/gravityforms.min.js?ver%3D2.10.5No marcado
https://www.myelomasociety.org/wp-content/plugins/gravityforms/js/jquery.json.min.js?ver%3D2.10.5No marcado
https://www.myelomasociety.org/wp-content/plugins/gravityforms/js/placeholders.jquery.min.js?ver%3D2.10.5No marcado
https://www.myelomasociety.org/wp-content/plugins/gravityforms/legacy/css/browsers.min.css?ver%3D2.10.5No marcado
https://www.myelomasociety.org/wp-content/plugins/gravityforms/legacy/css/formreset.min.css?ver%3D2.10.5No marcado
https://www.myelomasociety.org/wp-content/plugins/gravityforms/legacy/css/formsmain.min.css?ver%3D2.10.5No marcado
https://www.myelomasociety.org/wp-content/plugins/gravityforms/legacy/css/readyclass.min.css?ver%3D2.10.5No marcado
https://www.myelomasociety.org/wp-content/plugins/memberpress/css/ui/login.css?ver%3D1.12.17No marcado
https://www.myelomasociety.org/wp-content/plugins/memberpress/css/ui/theme.css?ver%3D1.12.17No marcado
https://www.myelomasociety.org/wp-content/plugins/memberpress/js/login.js?ver%3D1.12.17No marcado
https://www.myelomasociety.org/wp-content/plugins/podlove-podcasting-plugin-for-wordpress/css/admin-font.css?ver%3D4.5.4No marcado
https://www.myelomasociety.org/wp-content/plugins/podlove-podcasting-plugin-for-wordpress/css/frontend.css?ver%3D1.0No marcado
https://www.myelomasociety.org/wp-content/plugins/podlove-web-player/js/cache.js?ver%3D5.9.2No marcado
https://www.myelomasociety.org/wp-content/plugins/podlove-web-player/web-player/embed.js?ver%3D5.9.2No marcado
https://www.myelomasociety.org/wp-content/themes/myeloma-society/dist/scripts/main.js?ver%3D1778641861No marcado
https://www.myelomasociety.org/wp-content/themes/myeloma-society/dist/styles/main.css?ver%3D1778641860No marcado
https://www.myelomasociety.org/wp-content/uploads/2021/01/home3-1000x834.jpgNo marcado
https://www.myelomasociety.org/wp-content/uploads/2021/02/Jesus-San-Miguel-MD-PhD-320x410.jpgNo marcado
https://www.myelomasociety.org/wp-content/uploads/2021/02/Kenneth-Anderson-MD-320x410.jpgNo marcado
https://www.myelomasociety.org/wp-content/uploads/2021/02/Mateos-Maria-Victoria-320x410.jpgNo marcado
https://www.myelomasociety.org/wp-content/uploads/2021/02/Nikhil-C.-Munshi-MD-320x410.jpgNo marcado
https://www.myelomasociety.org/wp-content/uploads/2021/02/Philippe-Moreau-MD-320x410.jpgNo marcado
https://www.myelomasociety.org/wp-content/uploads/2021/02/Raje-Noopur-1-320x410.jpgNo marcado
https://www.myelomasociety.org/wp-content/uploads/2021/02/Robert-A.-Kyle-MD-320x410.jpgNo marcado
https://www.myelomasociety.org/wp-content/uploads/2021/02/Shaji-Kumar-MD-320x410.jpgNo marcado
https://www.myelomasociety.org/wp-content/uploads/2021/03/IMSMainLogo.pngNo marcado
https://www.myelomasociety.org/wp-content/uploads/2021/03/cropped-IMSAltLogo-180x180.pngNo marcado
https://www.myelomasociety.org/wp-content/uploads/2021/03/cropped-IMSAltLogo-192x192.pngNo marcado
https://www.myelomasociety.org/wp-content/uploads/2021/03/cropped-IMSAltLogo-32x32.pngNo marcado
https://www.myelomasociety.org/wp-content/uploads/2022/09/211125_SANOFI_LOGO_RGB.jpgNo marcado
https://www.myelomasociety.org/wp-content/uploads/2022/09/AbbVie-Logo_Blue-002.pngNo marcado
https://www.myelomasociety.org/wp-content/uploads/2022/11/GENE_LOCKUP_Primary_FullColor_RGB-002-2-1.pngNo marcado
https://www.myelomasociety.org/wp-content/uploads/2022/11/legend_logo_533x260-002-1.pngNo marcado
https://www.myelomasociety.org/wp-content/uploads/2023/08/shutterstock_775583896-745x419.jpgNo marcado
https://www.myelomasociety.org/wp-content/uploads/2023/10/2.-AbbVie-Logo-DigitalAbbVieLogo_Preferred-DigitalAbbVieLogo_Preferred_Black_TransparentBack-300x52.pngNo marcado
https://www.myelomasociety.org/wp-content/uploads/2023/10/20th-IMS-Annual-Meeting-Abstract-Book.pdfNo marcado
https://www.myelomasociety.org/wp-content/uploads/2023/10/Abe-Headshot-320x410.jpgNo marcado
https://www.myelomasociety.org/wp-content/uploads/2023/10/FDAIMSWorkshop2024Program-1.pdfNo marcado
https://www.myelomasociety.org/wp-content/uploads/2023/10/FDA_IMS-Joint-Wkshp-780x390-1-745x390.pngNo marcado
https://www.myelomasociety.org/wp-content/uploads/2023/10/JNJ_Logo_SingleLine_Red_RGB-1-002-300x28.pngNo marcado
https://www.myelomasociety.org/wp-content/uploads/2023/10/ReGEN_Science-Tagline-002-300x70.pngNo marcado
https://www.myelomasociety.org/wp-content/uploads/2023/10/Slide1-300x169.jpgNo marcado
https://www.myelomasociety.org/wp-content/uploads/2023/10/Usmani.jpgNo marcado
https://www.myelomasociety.org/wp-content/uploads/2023/10/Zamagni-Elena-320x410.jpgNo marcado
https://www.myelomasociety.org/wp-content/uploads/2023/10/bms_logo_150_rgb_pos-300x42.pngNo marcado
https://www.myelomasociety.org/wp-content/uploads/2024/04/Ochi-headshot-1.jpgNo marcado
https://www.myelomasociety.org/wp-content/uploads/2024/05/TMAP-Logo-scaled.jpgNo marcado
https://www.myelomasociety.org/wp-content/uploads/2024/06/IMSound-Logo-for-site-scaled.jpgNo marcado
https://www.myelomasociety.org/wp-content/uploads/2024/06/IMSound-Logo-scaled.jpgNo marcado
https://www.myelomasociety.org/wp-content/uploads/2024/07/IMSound-Logo-only-v2.pngNo marcado
https://www.myelomasociety.org/wp-content/uploads/2024/07/TMAP-Logo-scaled.jpgNo marcado
https://www.myelomasociety.org/wp-content/uploads/2024/08/JNJ_Logo_SingleLine_Red_CMYK-300x28.jpgNo marcado
https://www.myelomasociety.org/wp-content/uploads/2024/08/Practical-Insights-2024_1080-x-1080.jpg2_-745x419.jpgNo marcado
https://www.myelomasociety.org/wp-content/uploads/2024/10/AZ_RGB_H_COL-300x73.pngNo marcado
https://www.myelomasociety.org/wp-content/uploads/2024/10/IMSAnnual2024Abstracts.pdfNo marcado
https://www.myelomasociety.org/wp-content/uploads/2024/10/Sanofi-logo-RGB-JPG-300x138.jpgNo marcado
https://www.myelomasociety.org/wp-content/uploads/2024/10/bms_logo_300_rgb_pos-300x41.jpgNo marcado
https://www.myelomasociety.org/wp-content/uploads/2025/04/GSK_Logo_Full_Colour_RGB-300x169.pngNo marcado
https://www.myelomasociety.org/wp-content/uploads/2025/07/Full_Caribou_Logo_Dual_R-300x91.jpgNo marcado
https://www.myelomasociety.org/wp-content/uploads/2025/09/25IMS_004103-1-scaled.jpgNo marcado
https://www.myelomasociety.org/wp-content/uploads/2025/09/25IMS_004129-1-scaled.jpgNo marcado
https://www.myelomasociety.org/wp-content/uploads/2025/09/25IMS_004148-2-scaled.jpgNo marcado
https://www.myelomasociety.org/wp-content/uploads/2025/09/Chandramouli_Nagarajan.pngNo marcado
https://www.myelomasociety.org/wp-content/uploads/2025/09/IMS-Program-and-Initiatives-2025-Prf9.pdfNo marcado
https://www.myelomasociety.org/wp-content/uploads/2025/09/IMSAnnual2025Abstracts.pdfNo marcado
https://www.myelomasociety.org/wp-content/uploads/2025/09/Lentzsch-Suzanne-320x410.jpgNo marcado
https://www.myelomasociety.org/wp-content/uploads/2025/09/Natalia-Schutz.pngNo marcado
https://www.myelomasociety.org/wp-content/uploads/2025/09/Weisel-Katja-320x410.jpgNo marcado
https://www.myelomasociety.org/wp-content/uploads/2025/10/24IMSADA_01640-1000x750.jpgNo marcado
https://www.myelomasociety.org/wp-content/uploads/2025/10/25IMS_001072_Panel_Precursor-1000x750.jpgNo marcado
https://www.myelomasociety.org/wp-content/uploads/2025/10/25IMS_001681_Panel_Perrot-1000x568.jpgNo marcado
https://www.myelomasociety.org/wp-content/uploads/2025/10/25IMS_003079_Audience-1000x696.jpgNo marcado
https://www.myelomasociety.org/wp-content/uploads/2025/10/25IMS_004033_Poster-1000x750.jpgNo marcado
https://www.myelomasociety.org/wp-content/uploads/2025/12/GILEAD_KITE_Logo_Horiz_RGB_012622-300x93.jpgNo marcado
https://www.myelomasociety.org/wp-content/uploads/2025/12/IMS-2026-Graphics_940x789-745x419.jpgNo marcado
https://www.myelomasociety.org/wp-content/uploads/2025/12/Pfizer_BU_Oncology_Color_RGB-300x142.jpgNo marcado
https://www.myelomasociety.org/wp-content/uploads/2025/12/Roche_Logo_800px_Blue_RGB_Roche_Logo_RGB-3-300x156.pngNo marcado
https://www.myelomasociety.org/wp-content/uploads/2026/03/Abbvie-Community-300x114.pngNo marcado
https://www.myelomasociety.org/wp-content/uploads/2026/03/Community-Webinar-Graphics_940x789-1-745x419.jpgNo marcado
https://www.myelomasociety.org/wp-content/uploads/2026/03/Slide1-1-300x169.pngNo marcado
https://www.myelomasociety.org/wp-content/uploads/2026/03/Slide1-300x169.jpgNo marcado
https://www.myelomasociety.org/wp-content/uploads/2026/03/images-e1773728008617-300x60.jpgNo marcado
https://www.myelomasociety.org/wp-content/uploads/2026/05/IMS-GLO-Promos_1080x1080-1000x1000.jpgNo marcado
https://www.myelomasociety.org/wp-content/uploads/2026/07/IMS-2026-Media-Briefing-The-State-of-Multiple-Myeloma-Cure.pdfNo marcado
https://www.myelomasociety.org/wp-includes/css/dashicons.min.css?ver%3D7.0.4No marcado
https://www.myelomasociety.org/wp-includes/js/dist/a11y.min.js?ver%3Daf934e5259bc51b8718eNo marcado
https://www.myelomasociety.org/wp-includes/js/dist/dom-ready.min.js?ver%3Da06281ae5cf5500e9317No marcado
https://www.myelomasociety.org/wp-includes/js/dist/hooks.min.js?ver%3D7496969728ca0f95732dNo marcado
https://www.myelomasociety.org/wp-includes/js/dist/i18n.min.js?ver%3D781d11515ad3d91786ecNo marcado
https://www.myelomasociety.org/wp-includes/js/jquery/jquery-migrate.min.js?ver%3D3.4.1No marcado
https://www.myelomasociety.org/wp-includes/js/jquery/jquery.min.js?ver%3D3.7.1No marcado
https://www.myelomasociety.org/wp-includes/js/underscore.min.js?ver%3D1.13.8No marcado
https://www.vanguardngr.com/casino/de/online-casino-ohne-verifizierung/No marcado
https://x.com/Myeloma_SocietyNo marcado
browsehappy.comNo marcado
bsky.appNo marcado
cdn.jsdelivr.netNo marcado
challenges.cloudflare.comNo marcado
cloud.google.comNo marcado
developers.google.comNo marcado
docs.cloud.google.comNo marcado
events.jspargo.comNo marcado
fonts.googleapis.comNo marcado
fonts.gstatic.comNo marcado
google.comNo marcado
ims26.myexpoonline.comNo marcado
myeloma.wpengine.comNo marcado
myelomasociety.flexigrant.comNo marcado
myelomasociety.orgNo marcado
Mostrar 12 más...
player.vimeo.comNo marcado
support.google.comNo marcado
tmap.myelomasociety.orgNo marcado
vimeo.comNo marcado
www.eventcreate.comNo marcado
www.google.comNo marcado
www.googletagmanager.comNo marcado
www.gstatic.comNo marcado
www.linkedin.comNo marcado
www.myelomasociety.orgNo marcado
www.vanguardngr.comNo marcado
x.comNo marcado
<iframe title%3D"vimeo-player" src%3D"https://player.vimeo.com/video/1122004834?h%3D91c3f1bf02" width%3D"640" height%3D"360" frameborder%3D"0" allowfullscreen%3D"allowfullscreen">No marcado
Resumen de myelomasociety.org
Descripción de myelomasociety.org
myelomasociety.org parece ser el sitio web oficial de la International Myeloma Society, una organización centrada en la investigación, la educación, la defensa y la atención clínica del mieloma múltiple. La identidad visual de la página de inicio, el título de la página y los enlaces de navegación indican una asociación profesional u organización de estilo sin fines de lucro que presta servicio a clínicos, investigadores y miembros de la comunidad del mieloma en todo el mundo.
Según el contenido visible y las secciones enlazadas, el sitio parece proporcionar información sobre reuniones anuales, recursos educativos, iniciativas de investigación, premios, actividades de defensa, membresía y donaciones. El largo historial de registro del dominio y las clasificaciones relacionadas con salud/educación/defensa son coherentes con la presencia de una sociedad médica u ONG establecida, en lugar de un sitio promocional temporal.
Evaluación de seguridad de myelomasociety.org
En el momento de este análisis, ningún motor de seguridad informó detecciones para este dominio, y el análisis de malware indicó que no había archivos marcados entre las páginas comprobadas. Además, el dominio no figuraba en las bases de datos de listas negras orientadas a malware y phishing que se comprobaron, y los enlaces y dominios externos referenciados no mostraron elementos marcados en los resultados del análisis proporcionados.
Otras señales contextuales también parecen favorables. El dominio ha estado registrado durante muchos años, el contenido del sitio coincide con el de una organización orientada a la salud y la defensa, y la captura de pantalla muestra un sitio web institucional coherente en lugar de patrones comúnmente asociados con phishing, tiendas falsas o distribución de malware. Según los datos disponibles, no se detectaron amenazas en el momento de este análisis.
Descripción técnica
El sitio está utilizando un certificado SSL/TLS válido emitido por Let's Encrypt, y el certificado se muestra como vigente hasta 2026-10-02. Está alojado en infraestructura de Google Cloud en Estados Unidos, utiliza el servidor web nginx y sus nameservers están configurados mediante infraestructura relacionada con Google Domains.
DNSSEC parece estar habilitado y firmado, lo que puede ayudar a proteger la integridad del DNS. No se observaron preocupaciones técnicas de seguridad inmediatas en los datos del análisis proporcionados, aunque los detalles exactos de los protocolos TLS compatibles no estaban disponibles en esta instantánea.
Cadena de redirección HTTP
301
https://myelomasociety.org/
200
https://www.myelomasociety.org/
Información del sitio web
Popularidad
Cookies
Sin clasificar
Ranking Tranco
No está en el Top 1M
Historial de ranking (30 días)
No hay datos de clasificación disponibles
3
cookies detectadas
Esenciales0
Analíticas2
Publicidad1
Social0
3
cookies de 1.ª parte
0
de 3.ª parte (rastreadores)
Impugnar esta puntuación
Para propietarios web
¿Cree que esta puntuación es inexacta?
Si es el propietario del sitio web y cree que los resultados del análisis contienen errores o falsos positivos, puede enviar una impugnación para revisión manual. Nuestro equipo suele responder en 1-2 días laborables.
Un paso más…
Para enviar su impugnación de myelomasociety.org, haga clic en el enlace de verificación que le acabamos de enviar por correo. Una vez verificada, la revisaremos en 1-2 días laborables.
Este informe se generó automáticamente y se proporciona solo con fines informativos. Los resultados se basan en un análisis puntual y pueden contener falsos positivos o datos incompletos. Esto no constituye una auditoría ni una certificación de seguridad. Ningún proveedor del mercado puede garantizar una tasa de detección del 100%. Si cree que este informe es inexacto, por favor
envíe una disputa.
Similares analizados recientemente
Comparta su experiencia con este sitio web. ¿Era seguro? ¿Tuvo algún problema?